Home/Filings/4/0001209191-21-021223
4//SEC Filing

CEDARS SINAI MEDICAL CENTER 4

Accession 0001209191-21-021223

CIK 0001718852other

Filed

Mar 15, 8:00 PM ET

Accepted

Mar 16, 9:53 PM ET

Size

23.1 KB

Accession

0001209191-21-021223

Insider Transaction Report

Form 4
Period: 2021-03-16
Transactions
  • Conversion

    Common Stock

    2021-03-16+361,5665,008,508 total
  • Conversion

    Series C Preferred Stock

    2021-03-1625,000,0000 total
    Common Stock (2,500,000 underlying)
  • Conversion

    Series D-2 Preferred Stock

    2021-03-163,615,6560 total
    Common Stock (361,566 underlying)
  • Conversion

    Common Stock

    2021-03-16+1,200,0001,892,500 total
  • Conversion

    Common Stock

    2021-03-16+254,4424,646,942 total
  • Conversion

    Series A Preferred Stock

    2021-03-161,000,0000 total
    Common Stock (100,000 underlying)
  • Conversion

    Series B Preferred Stock

    2021-03-1612,000,0000 total
    Common Stock (1,200,000 underlying)
  • Conversion

    Common Stock

    2021-03-16+100,000692,500 total
  • Conversion

    Common Stock

    2021-03-16+2,500,0004,392,500 total
  • Conversion

    Series D-1 Preferred Stock

    2021-03-162,544,4250 total
    Common Stock (254,442 underlying)
Footnotes (5)
  • [F1]The shares of the Issuer's Series A Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering.
  • [F2]The shares of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering.
  • [F3]The shares of the Issuer's Series C Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering.
  • [F4]The shares of the Issuer's Series D-1 Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering.
  • [F5]The shares of the Issuer's Series D-2 Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering.

Issuer

Prometheus Biosciences, Inc.

CIK 0001718852

Entity typeother
IncorporatedCA

Related Parties

1
  • filerCIK 0001269910

Filing Metadata

Form type
4
Filed
Mar 15, 8:00 PM ET
Accepted
Mar 16, 9:53 PM ET
Size
23.1 KB